Afinitor shown to delay tumor growth in HER2+ advanced breast cancer
HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2) positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers report.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter